Open access
Open access
Powered by Google Translator Translator

Oncology – Gastrointestinal

Dysplastic recurrence after successful treatment for early Barrett’s neoplasia: development and validation of a prediction model.

24 Jun, 2022 | 11:07h | UTC

Dysplastic Recurrence After Successful Treatment for Early Barrett’s Neoplasia: Development and Validation of a Prediction Model – Gastroenterology

 


Consensus report on anatomy, pathophysiology and clinical significance of the gastro-esophageal junction.

23 Jun, 2022 | 10:26h | UTC

Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction – Gut

 


Phase II RCT: FLOT vs. FLOT/Trastuzumab/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2–positive resectable esophagogastric adenocarcinoma.

23 Jun, 2022 | 09:58h | UTC

FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group – Journal of Clinical Oncology (link to abstract – $ for full-text)

 


RCT: In people with HIV, treating precancerous anal lesions cuts risk of anal cancer by more than half.

21 Jun, 2022 | 11:11h | UTC

News Release: In people with HIV, treating precancerous anal lesions cuts risk of anal cancer by more than half – National Institutes of Health

Original Study: Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Clinical and immunologic analyses of a phase II trial: Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer.

21 Jun, 2022 | 10:26h | UTC

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial – Nature Medicine

News Release: Promising results for chemo-immunotherapy combination against pancreatic cancer, Penn study finds – University of Pennsylvania

 

Commentary on Twitter

 


Radiomic assessment of esophageal adenocarcinoma: a critical review of 18F-FDG PET/CT, PET/MRI and CT.

20 Jun, 2022 | 00:53h | UTC

Radiomic assessment of oesophageal adenocarcinoma: a critical review of 18F-FDG PET/CT, PET/MRI and CT – Insights into Imaging

 


Short-term and oncological outcomes of natural orifice specimen extraction surgery (NOSES) for colorectal cancer in China: a national database study of 5055 patients.

15 Jun, 2022 | 10:49h | UTC

Short-term and oncological outcomes of natural orifice specimen extraction surgery (NOSES) for colorectal cancer in China: a national database study of 5055 patients – Science Bulletin

News Release: Short-term and oncological outcomes of natural orifice specimen extraction surgery (NOSES) for colorectal cancer – Science China Press

 


ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility.

14 Jun, 2022 | 10:59h | UTC

ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations – Gastrointestinal Endoscopy

Commentary: New guidelines for pancreatic cancer screening – Beth Israel Deaconess Medical Center

 

Commentary on Twitter

 


Causes of liver cancer are changing around the world: some up, some down.

13 Jun, 2022 | 07:54h | UTC

News Release: Causes of Liver Cancer are Changing Around the World: Some Up, Some Down – UC San Diego Health

Original Study: Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer – Cell Metabolism (link to abstract – $ for full-text)

 


RCT: Tremelimumab plus Durvalumab in unresectable hepatocellular carcinoma.

9 Jun, 2022 | 10:24h | UTC

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma – NEJM Evidence

 

Commentary on Twitter

 


Phase 2 RCT: Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer.

9 Jun, 2022 | 10:19h | UTC

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Prolonged PFS Observed With Addition of Atezolizumab to FOLFOXIRI and Bevacizumab for Metastatic CRC – Cancer Network

 

Commentary on Twitter

 


Systematic Review: Guaiac‐based fecal occult blood tests versus fecal immunochemical tests for colorectal cancer screening in average‐risk individuals.

8 Jun, 2022 | 10:59h | UTC

Guaiac‐based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average‐risk individuals – Cochrane Library

Summary: Which faecal blood test is more accurate in detecting bowel cancer and large polyps in population screening? – Cochrane Library

 

Commentary on Twitter

 


#ASCO22 – RCT: Upfront modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan plus Panitumumab vs. Fluorouracil, Leucovorin, and Oxaliplatin plus Panitumumab for patients with RAS/BRAF wild-type metastatic colorectal cancer.

7 Jun, 2022 | 10:49h | UTC

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO – Journal of Clinical Oncology

 


#ADA2022 – Retrospective Cohort Study: Association of bariatric surgery with cancer risk and mortality in adults with obesity.

6 Jun, 2022 | 11:54h | UTC

Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity – JAMA (free for a limited period)

Editorial: Bariatric Surgery and Cancer Risk – JAMA (free for a limited period)

News Release: Weight loss with bariatric surgery cuts the risk of developing cancer and death from cancer – Cleveland Clinic

 

Commentaries on Twitter

 


#ASCO22 – RCT: Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer.

6 Jun, 2022 | 11:53h | UTC

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: DNA shed from colon cancers into bloodstream successfully guides chemotherapy after surgery – Helps clarify the benefit of chemotherapy in stage II cancers – Johns Hopkins Medicine

Commentary: ctDNA Effectively Detects When Adjuvant Chemo Is Avoidable in Stage II Colon Cancers – Cancer Network

 

Commentary on Twitter

 


#ASCO22 – Phase 2 single-arm study: PD-1 Blockade in mismatch repair–deficient, locally advanced rectal cancer.

6 Jun, 2022 | 11:12h | UTC

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

 


Consensus Statement: Current role of immunotherapy in gastric, esophageal and gastro-esophageal junction cancers.

3 Jun, 2022 | 11:24h | UTC

Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Cancers—A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference – Current Oncology

 


Review: Integration of genomic biology into therapeutic strategies of gastric cancer peritoneal metastasis.

3 Jun, 2022 | 10:51h | UTC

Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis – Journal of Clinical Oncology

 


M-A: Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer.

3 Jun, 2022 | 10:46h | UTC

Neoadjuvant Short-Course Radiotherapy Followed by Consolidation Chemotherapy before Surgery for Treating Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis – Current Oncology

 


RCT: Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.

2 Jun, 2022 | 10:49h | UTC

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer – NEJM Evidence

 

Commentary on Twitter

 


Retrospective Cohort Study: Colonoscopy surveillance following adenoma removal to reduce the risk of colorectal cancer.

1 Jun, 2022 | 11:17h | UTC

Colonoscopy surveillance following adenoma removal to reduce the risk of colorectal cancer: a retrospective cohort study – Health Technology Assessment

 


Update on perioperative management of patients undergoing surgery for liver cancer.

1 Jun, 2022 | 11:11h | UTC

Update on perioperative management of patients undergoing surgery for liver cancer – Annals of Gastroenterological Surgery

 


Long-term impact of Helicobacter pylori eradication therapy on gastric cancer incidence and mortality in healthy infected individuals: A meta-analysis beyond 10 years of follow-up.

31 May, 2022 | 11:47h | UTC

Long-term impact of Helicobacter pylori eradication therapy on gastric cancer incidence and mortality in healthy infected individuals: A meta-analysis beyond 10 years of follow-up – Gastroenterology

 

Commentary from the author on Twitter (thread – click for more)

 


RCT: Rivaroxaban vs. placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer.

31 May, 2022 | 11:19h | UTC

Rivaroxaban versus placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer – Blood

 


Current guidelines in the surgical management of hereditary colorectal cancers.

27 May, 2022 | 12:00h | UTC

Current guidelines in the surgical management of hereditary colorectal cancers – World Journal of Gastrointestinal Oncology

 


Stay Updated in Your Specialty

No spam, just news.